Filtered By:
Specialty: Hematology
Condition: Heart Failure
This page shows you your search results in order of date. This is page number 7.
Order by Relevance | Date
Total 178 results found since Jan 2013.
Platelets and COVID-19
Hamostaseologie. 2021 Oct;41(5):379-385. doi: 10.1055/a-1581-4355. Epub 2021 Oct 25.ABSTRACTIn 2019 first reports about a new human coronavirus emerged, which causes common cold symptoms as well as acute respiratory distress syndrome. The virus was identified as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and severe thrombotic events including deep vein thrombosis, pulmonary embolism, and microthrombi emerged as additional symptoms. Heart failure, myocardial infarction, myocarditis, and stroke have also been observed. As main mediator of thrombus formation, platelets became one of the key aspects in SARS-C...
Source: Hamostaseologie - October 25, 2021 Category: Hematology Authors: Anne-Katrin Rohlfing Dominik Rath Tobias Geisler Meinrad Gawaz Source Type: research
Antithrombotic strategy and its relationship with outcomes in patients with atrial fibrillation and chronic coronary syndrome
This study aimed to explore antithrombotic strategy and its relationship with outcomes in patients with atrial fibrillation (AF) at high risk for stroke and chronic coronary syndrome (CCS) in real-world clinical practice. Patients with AF at high risk for stroke complicated with CCS from China Atrial Fibrillation Registry (CAFR) were enrolled. The patients were divided into non-antithrombotic (Non-AT) group, oral anticoagulants (OAC) group, antiplatelet therapy (APT) group (aspirin or clopidogrel), and dual antiplatelet therapy (DAPT) group (aspirin + clopidogrel) according to their antithrombotic strategies at baseli...
Source: Journal of Thrombosis and Thrombolysis - October 22, 2021 Category: Hematology Source Type: research
Cardiovascular Mortality after Venous Thromboembolism: A Meta-Analysis of Prospective Cohort Studies
Semin Thromb Hemost DOI: 10.1055/s-0041-1733923Many studies from current literature show that cardiovascular diseases in patients with venous thromboembolism (VTE) are more frequent than in the general population without VTE. However, data summarizing the impact of cardiovascular diseases on mortality of patients with VTE are lacking. In this systematic review and meta-analysis, we aimed to determine the frequency and incidence rate of cardiovascular death in patients with VTE. MEDLINE and EMBASE were searched from January 1, 2000 to February 28, 2021. Eligible studies were observational prospective cohort studies includin...
Source: Seminars in Thrombosis and Hemostasis - October 8, 2021 Category: Hematology Authors: Noumegni, Steve Raoul Grangereau, Thomas Demir, Arzu Bressollette, Luc Couturaud, Francis Hoffmann, Cl ément Tags: Review Article Source Type: research
Reduced-dose intravenous thrombolysis for acute intermediate high-risk pulmonary embolism: Rationale and design of the PEITHO-3 trial
Thromb Haemost. 2021 Sep 24. doi: 10.1055/a-1653-4699. Online ahead of print.ABSTRACTIntermediate high-risk pulmonary embolism (PE) is characterised by right ventricular (RV) dysfunction and elevated circulating cardiac troponin levels despite apparent haemodynamic stability at presentation. In these patients, full-dose systemic thrombolysis reduced the risk of haemodynamic decompensation or death but increased the risk of life-threatening bleeding. Reduced-dose thrombolysis may be capable of improving safety while maintaining reperfusion efficacy. The Pulmonary Embolism International Trial (PEITHO)-3 study (EudraCT 2018-0...
Source: Thrombosis and Haemostasis - September 24, 2021 Category: Hematology Authors: Olivier Sanchez Anais Charles-Nelson Walter Ageno Stefano Barco Harald Binder Gilles Chatellier Daniel Duerschmied Klaus Empen Melanie Ferreira Philippe Girard Menno V Huisman David Jim énez Sandrine Katsahian Matija Kozak Mareike Lankeit Nicolas Menevea Source Type: research
Extended-Duration Low-intensity Apixaban to Prevent Recurrence in Patients with Provoked Venous Thromboembolism: Design of the HI-PRO Trial
Thromb Haemost. 2021 Sep 16. doi: 10.1055/a-1646-2244. Online ahead of print.ABSTRACTPatients with acute venous thromboembolism (VTE) in the setting of transient provoking factors are typically treated with short-term anticoagulation. However, the risk of recurrence may be increased in the presence of enduring risk factors. In such patients, the optimal duration of treatment remains uncertain. HI-PRO is a single-center, double-blind randomized trial. Patients with deep vein thrombosis (DVT) or pulmonary embolism (PE) following a major provoking factor, including major surgery or major trauma, who completed at least 3 month...
Source: Thrombosis and Haemostasis - September 16, 2021 Category: Hematology Authors: Behnood Bikdeli Heather Hogan Ruth Morrison John Fanikos Umberto Campia Briana Barns Mariana Pfeferman Julia Snyder Candrika Khairani Samuel Z Goldhaber Gregory Piazza Source Type: research
Oral anticoagulation for patients with atrial fibrillation in the ED: RE-LY AF registry analysis
AbstractOral anticoagulation (OAC) reduces stroke risk in patients with atrial fibrillation (AF). We sought to determine predictors of OAC initiation in AF patients presenting to the emergency department (ED). Secondary analysis of the RE-LY AF registry which enrolled individuals from 47 countries between 2007 and 2011 who presented to an ED with AF and followed them for 1 year. A total of 4149 patients with AF as their primary diagnosis who were not already taking OAC and had a CHA2DS2-VASc ≥ 1 for men or ≥ 2 for women were included in this analysis. Of these individuals, 26.8% were started on OAC (99.2% vi...
Source: Journal of Thrombosis and Thrombolysis - August 2, 2021 Category: Hematology Source Type: research
Traditional risk factors and combined genetic markers of recurrent ischemic stroke in adults
CONCLUSIONS: Our findings suggest that cumulative effect of both traditional and common genetic risk factors were associated with recurrence of ischemic stroke. We demonstrated for the first time that a combined genotype FVL/MTHFR profile increase the risk of a second cerebral ischemic attack.PMID:34241942 | DOI:10.1111/jth.15448
Source: Thrombosis and Haemostasis - July 9, 2021 Category: Hematology Authors: Lamia M'barek Salma Sakka Fatma Megdiche Nouha Farhat Khadija Maalla Dhaker Turki Sawsan Feki Ahmed Rebai Mariem Dammak Choumous Kallel Chokri Mhiri Source Type: research
Not-high before-treatment platelet reactivity in patients with STEMI: prevalence, clinical characteristics, response to therapy and outcomes
In conclusion, a significant proportion of patients presenting with STEMI has a baseline NHPR that is associated with better in-hospital outcomes as compared with patients with HPR. Further studies are needed to better elucidate the potential therapeutic implications of NHPR in terms of secondary prevention.PMID:33856272 | DOI:10.1080/09537104.2021.1915973
Source: Platelets - April 15, 2021 Category: Hematology Authors: Mario E Canonico Giuseppe D Sanna Roberta Siciliano Simona Guarino Benedetta Bellandi Fernando Scudiero Pier Sergio Saba Giovanni Esposito Dimitrios Alexopoulos Guido Parodi Source Type: research
